These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10332633)

  • 1. Innovations in integrated dual diagnosis treatment in public managed care: the Choate dual diagnosis case rate program.
    Minkoff K; Regner J
    J Psychoactive Drugs; 1999; 31(1):3-12. PubMed ID: 10332633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managed care and the quality of substance abuse treatment.
    Shepard DS; Daley M; Ritter GA; Hodgkin D; Beinecke RH
    J Ment Health Policy Econ; 2002 Dec; 5(4):163-74. PubMed ID: 14578550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancing services for offenders: the impact on treatment completion.
    Arnold EM; Stewart JC; McNeece CA
    J Psychoactive Drugs; 2001; 33(3):255-62. PubMed ID: 11718318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual diagnosis demonstration project: treatment outcomes and cost analysis.
    Judd PH; Thomas N; Schwartz T; Outcalt A; Hough R
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():181-92. PubMed ID: 12825761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Dual Diagnosis Capability of Residential Addiction Treatment centres: priorities and confidence to improve capability following a review process.
    Matthews H; Kelly PJ; Deane FP
    Drug Alcohol Rev; 2011 Mar; 30(2):195-9. PubMed ID: 21355921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organizational capacity to address co-occurring substance use and psychiatric disorders: assessing variation by level of care.
    Lambert-Harris C; Saunders EC; McGovern MP; Xie H
    J Addict Med; 2013; 7(1):25-32. PubMed ID: 23188042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assertive Community Treatment for patients with chronic and severe mental illness who abuse drugs.
    Wingerson D; Ries RK
    J Psychoactive Drugs; 1999; 31(1):13-8. PubMed ID: 10332634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managed care, networks and trends in hospital care for mental health and substance abuse treatment in Massachusetts: 1994-1999.
    Fleming E; Lien H; Ma CT; McGuire TG
    J Ment Health Policy Econ; 2003 Mar; 6(1):3-12. PubMed ID: 14578543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breaking the cycle of dependency: dual diagnosis and AFDC families.
    Bearman D; Claydon K; Kincheloe J; Lodise C
    J Psychoactive Drugs; 1997; 29(4):359-67. PubMed ID: 9460030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROTOTYPES: an urban model program of treatment and recovery services for dually diagnosed perinatal program participants.
    Mosley TM
    J Psychoactive Drugs; 1996; 28(4):381-8. PubMed ID: 9017558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for dual diagnosis patients in the psychiatric and substance abuse systems.
    Timko C; Dixon K; Moos RH
    Ment Health Serv Res; 2005 Dec; 7(4):229-42. PubMed ID: 16320106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with high levels of spending for younger dually eligible beneficiaries with mental disorders.
    Frank RG; Epstein AM
    Health Aff (Millwood); 2014 Jun; 33(6):1006-13. PubMed ID: 24889950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual diagnosis typology to improve diagnosis and treatment of dual disorder patients.
    Zimberg S
    J Psychoactive Drugs; 1999; 31(1):47-51. PubMed ID: 10332638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addiction medicine in the '90s: a case study.
    Brandenburger JS
    Calif Hosp; 1993; 7(1):12-3. PubMed ID: 10171357
    [No Abstract]   [Full Text] [Related]  

  • 15. The Addiction Treatment Unit: a dual diagnosis program at the California Medical Facility--a descriptive report.
    Katz RI
    J Psychoactive Drugs; 1999; 31(1):41-6. PubMed ID: 10332637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severely and persistently mentally ill substance abusers: clinical and policy issues.
    Zweben JE
    J Psychoactive Drugs; 2000; 32(4):383-9. PubMed ID: 11210200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral interventions for dual-diagnosis patients.
    Goldsmith RJ; Garlapati V
    Psychiatr Clin North Am; 2004 Dec; 27(4):709-25. PubMed ID: 15550289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dialogue: can managed behavioral healthcare plans serve the severely mentally ill? Dual diagnoses raise special challenges.
    Shumway DL
    Behav Healthc Tomorrow; 1994; 3(2):41, 47-8. PubMed ID: 10141410
    [No Abstract]   [Full Text] [Related]  

  • 20. Increasing program capability to provide treatment for co-occurring substance use and mental disorders: organizational characteristics.
    Gotham HJ; Claus RE; Selig K; Homer AL
    J Subst Abuse Treat; 2010 Mar; 38(2):160-9. PubMed ID: 19717273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.